88/100 A · Moderate risk
No major risk flags in the public sources we cover Indicative TraceComp estimate from public sources — an automated indicator, not a credit decision, a completed due-diligence check, or a guarantee. Verify against the official register.

ℹ️ No matches surfaced in the limited public sources we cover (sanctions, screening, insolvency, control). This is an automated indicator — not an exhaustive check, a credit decision, or a guarantee, and absence of a match does not mean none exists. Verify against the official register.

Think this is wrong? This is an automated estimate — request a human review or correction.

INNOTHERA

Active Simplified joint-stock company (SAS) Financial services Active for 126 years

Simplified joint-stock company (SAS) · RC 302587662 · Active since 1900

A

Overview

INNOTHERA is a simplified joint-stock company (sas) registered in France, since 1900. The company operates in the financial services sector. With reported revenue of 241.9M EUR in 2024. Its TraceComp score of 88 (A) indicates solid fundamentals and low apparent risk. With 126 years of operations, the company has an established track record in its market.

Company Information

Registration Number
302587662
Legal Form
Simplified joint-stock company (SAS)
Registered
1900-01-01

Financial Profile

Latest filed accounts: FY 2024

Revenue (2024) 241,876,000 EUR
Net Income —
Total Assets 211,208,000 EUR
Altman Z 2.28 grey

Multi-year financials & ratios

5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Research Output

Active research organization. 152 publications · 9,670 citations · h-index 50 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Medicine (88%) · Immunology and Microbiology (13%).

See full research profile — top researchers & publications →

Source: OpenAlex (CC0). Objective publication & citation counts.

Patent Portfolio

Active patent holder. 12 patents · 12 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Corporate Group & Ownership

Parent entities from the GLEIF global ownership graph (LEI Level 2).

RelationshipParent entityCountry
Direct parent JABER FINANCES FR
Ultimate parent JABER FINANCES FR

Risk Signals

No adverse legal events have been recorded for this company.

No risk signals detected.

Data Sources & Freshness

Data sourced from: bulk register.